Menu

Pharmaceuticals

 

 

Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity

, , , ,

The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays Basel, 2 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets accepting the CE mark. The […]

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

, , ,

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 25, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Zydelig® (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients […]

Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries

, , ,

Agreement provides license for generic production of tenofovir alafenamide, an investigational agent for the treatment of HIV and chronic hepatitis B MELBOURNE, Australia–(BUSINESS WIRE)–Jul. 24, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s […]

U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

, , ,

82 Percent Reduction in Risk of Disease Progression or Death When Combined with Rituximab Compared to Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 23, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) 150 mg tablets for the […]

Bayer Early Excellence in Science Award: EUR 30,000 for international research scientists

, , ,

Dr. Abigail Doyle (Associate Professor at Princeton University, USA) wins the „Chemistry“ category / Dr. Steven Spoel (Principal Investigator at the University of Edinburgh, UK) takes the „Biology“ award /Dr. Javier Fernandez (Associate Researcher at Wyss Institute/Harvard University, Boston, USA) awarded prize in the „Materials“ field Leverkusen, January 10, 2013 – The winners of the Bayer […]

Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies

, , , ,

Cambridge, Mass and Richmond, Calif. –  January 9, 2014 – Biogen Idec (NASDAQ:BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The agreement will enable Biogen Idec to further enhance its […]

Bayer Leads Unique Effort to Support Global Public Health by Fighting Vector-Borne Diseases

, , ,

Special global web conference “One Health” to address zoonotic disease within the veterinary and public health fields Leverkusen, January 9, 2014 – Nearly half of the world’s population is infected with at least one type of vector-borne disease (1). These diseases are transmitted from parasites to animals and humans, and have a significant impact on public health […]

Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology

, , ,

NEW YORK, Jan. 9, 2014 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. FLINT is a multi-center, double-blind, placebo-controlled […]

Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference

, , ,

RICHMOND, Calif., Jan. 8, 2014 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo’s president and chief executive officer, will present an update on Sangamo’s clinical and preclinical ZFP Therapeutic® programs and upcoming milestones, as well as an overview of the Company’s business strategy at the 32ND AnnualJ.P. Morgan Healthcare Conference on Thursday, January 16TH at 11:00 am PT in San Francisco. “Sangamo […]

«‹ 17 18 19 20›»